MGRX MGRX
Company Profile ↓Company Overview
MGRX (MGRX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 270.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $456.02K (-26.0% YoY); net profit $-20.64M.
- Trailing 12 Months Year-on-year growth — revenue -26.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 270.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 270.88% |
| 1 Year: | -25.96% |
Stock Price Performance
| 1 Year: | -75.69% |
| 6 Months: | +8.82% |
| 3 Months: | +32.97% |
| 1 Month: | +14.08% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)48.35 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 270.9% over 5 years.
CONS
- Trading 84.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 100.72K | 141.24K | 245.16K | 214.09K | 163.16K | 133.37K | 109.31K | 168.11K | 84.25K | 67.86K |
| Gross Profit | - | - | - | 57.20K | 87.13K | 144.59K | 147.40K | 69.79K | 82.67K | 62.06K | 89.95K | 50.90K | 29.00K |
| Operating Income | -18.71K | -327.90K | -991.83K | -2.56M | -2.29M | -1.80M | -2.37M | -2.17M | -1.76M | -4.58M | -5.27M | -7.54M | -3.13M |
| Net Income | -19.60K | -310.19K | -994.91K | -2.56M | -2.28M | -1.80M | -2.37M | -2.39M | -2.00M | -4.84M | -5.42M | -7.62M | -3.40M |
| Diluted EPS | - | -0.04 | -0.10 | -0.23 | -0.14 | -1.70 | -1.50 | -1.37 | -1.14 | -1.12 | -0.57 | -0.69 | -0.22 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 8.94K | 731.49K | 615.87K | 456.02K |
| Gross Profit | 4.85K | 431.50K | 379.96K | 250.39K |
| Operating Income | -1.99M | -9.22M | -7.97M | -18.03M |
| Net Income | -2.00M | -9.21M | -8.71M | -20.64M |
| Diluted EPS | -0.19 | -8.58 | -4.80 | -2.17 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.00M | 1.05M | 15.37M | 16.09M |
| Total Equity | -16.72K | 614.03K | 774.75K | 13.95M | 15.20M |
| Cash & Equivalents | - | 682.86K | 739.01K | 58.65K | 1.49M |
| Total Liabilities | - | 389.26K | 276.04K | 1.43M | 890.57K |
| Current Liabilities | - | 260.58K | 211.08K | 1.43M | 890.57K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.35M | -7.00M | -4.86M | -5.85M |
| Investing Cash Flow | -43.10K | -3.52K | 65.00K | - |
| Financing Cash Flow | 2.05M | 7.06M | 4.13M | 7.27M |
| Capital Expenditure | -43.10K | -3.52K | - | - |
| Free Cash Flow | -1.39M | -7.00M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 54.3% | 59.0% | 61.7% | 54.9% |
| Operating Margin % | -22,279.7% | -1,260.3% | -1,294.4% | -3,954.3% |
| Net Margin % | -22,352.1% | -1,259.4% | -1,413.6% | -4,526.8% |
| ROE % | -325.4% | -1,189.1% | -62.4% | -135.8% |
| ROCE % | -268.2% | -1,097.9% | -57.2% | -118.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MGRX
Utah Lab and Nuclea Explore Morpheus Test-Reactor Site - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPcjlfcUpxb2s0TllNNERwVjlyVEwwSVNSSnBKT3E1bTNFek1pY3NJRl9HX25GZDJxTkFKQTJVbzFkMTFVVWIzNGFVS2hyQTE2Ykd1a2RPX3lZeDFXOUhOYk1LYU5CanhBbWM0c3Q1T0VOQWo0U05GRU95SlRFSFR3WjladUllUGFnaDR4WW…
Mangoceuticals (MGRX) Stock Jumps 138% After Hours On Nuclear Reactor Deal: Here's Why It Is Trending Man - Benzinga
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOaXY2eFBMRTdmWllFb1dwVXRxWDFtZjUzbm54TTdXSnBTOFNydWxlMWFicmlTNGJCTWpFU18wOGZCVTNkZVgtcV9odjVlSk9tLVBUTEZLeUw3ajJIRDZKZWhMNmE4aTB0aGJ3WGpkQjEtaTlxVm9RRXFnMlJNYzQ2SV9SYmthUDJ4TnlvNG…
Market Movers | Winners: FWAC, REPL, MGRX | Losers: KPTI, BIOA, MBRX - Trefis
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQXzBCRUREcDlWY0c1eXFTMDlSWUQydGFPdUFkTnFlclRqdV9sRnF3R0ZGOGp0aWZEWnhMaTdXcnVuQXV4cDdkbklQMEJXOFo3NFFqam16ZC1vTXVOcWwxX0pfNEEtenNaZ1RKZVlQcUtTdHc2MzF1T2tGMllYMVMtWEZ0dG1aZWszLTBBZl…
MGRX surges after Nuclea Energy reverse-merger deal reshapes company story - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT0pybS0zLWVJSjUwU202SnpMSk1WWmMzS3hhTmxqbUwxR0ZuYUlBdDhFcGNQWTNvQ1FONmxObDBrTjVxdVQ1LWwwVjhpQU9MTzVPeUZ1QklZc3lONTEzT0NES3RnQXVibTB5RTRPN0kzMm16RDJ4YWJUVXByR0d6eVJwVm9SMjNISXAwUU…
Thursday's after hours session: top gainers and losers - ChartMill
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOZlZOSUk4dGx4YlpLYV9pSGJlbHBTVzdMS1h2NHBKOHBZRVFDS09Fb2NIN0FialJWaVMxcVhkZGhQbWpvTjN1R1ExcUx3elZuOG1PYWYtcTU1aXBMZmdtNUEzNFJLaG5UUzNiUmR0QndnSVBFRFJoV1lUbHFDUWdsMTBsMDByenFjV3lGck…
$Mangoceuticals (MGRX.US)$ - Moomoo
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxNdEIwa1FsWEducklITHB5VTJKSVljV3hhbFZWZGN0Vlp2cV8wOUVCTVRpOHY3ZzI4S2JETXBjS3kwTlQzVDBRbzJQa2F1RXJBTFlaTWhKNWVPc2FSV21JY0lPMXBNME0zV1Vzdjc5NU5tTzhQd2hrNXpxUjhTQUtIYmxR?oc=5" target=…
MGRX — Frequently Asked Questions
What is the current share price of MGRX?
As of 2026-08-05 17:25 PDT, MGRX trades at $0.43 on NASDAQ/NYSE. Its 52-week range is $0.16 to $2.74.
What is the P/E ratio of MGRX?
MGRX trades at a trailing price-to-earnings (P/E) ratio of -0.20.
What is the return on equity (ROE) of MGRX?
MGRX has a return on equity (ROE) of -135.80%. Its return on capital employed (ROCE) is -118.64%.
Is MGRX a good stock to buy?
This page provides a data-driven analysis of MGRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.